Parvovirus B19 infection in Tunisian patients with sickle-cell anemia and acute erythroblastopenia

Regaya, Faouzi; Oussaief, Lassad; Béjaoui, Mohamed; Karoui, Mongi; Zili, Mohamed; Khelifa, Ridha

doi:10.1186/1471-2334-7-123

Cited by 25 publications

(25 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The study showed a very high incidence of B19 IgG among the study group (56.5%). [1] This difference in B19 incidence comes in agreement with various epidemiological reports indicating that this infection spreads at a high rate in low age groups to reach 50% of young adolescents by age 15, and continues at a lower rate throughout adult life to reach most of the elderly. Another study that was conducted in Egypt showed an IgG prevalence of 61% among paediatric patients suffering from various malignancies.…”

Section: Discussionsupporting

confidence: 87%

See 1 more Smart Citation

Detection of human parvovirus B19 in cancer patients using ELISA and real-time PCR

2012

Indian Journal of Medical Microbiology

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 87%

“…In immunocompetent individuals B19 infections can be asymptomatic or benign. [1] Immunodeficient subjects may become chronically infected. It causes a wide range of human diseases, including a febrile rash illness called erythema infectiosum or fifth disease, severe anaemia and transient aplastic crisis.…”

Section: Introductionmentioning

confidence: 99%

Detection of human parvovirus B19 in cancer patients using ELISA and real-time PCR

2012

Indian Journal of Medical Microbiology

View full text Add to dashboard Cite

show abstract

“…In our study, the antibody prevalence was found to be 72.2% in adults with rheumatoid arthritis and 43.8% in children with juvenile rheumatoid arthritis. Likewise, in association with diseases of the blood and blood-forming organs, and in disorders involving the immune mechanism, a study conducted in Tunisia by Regaya et al (21) showed that B19 IgG antibody positivity was 56.5% in patients with sickle cell anemia and 39.1% in patients with beta thalassemia. In Nigeria, IgG and IgM antibody positivity was 61.6% and 17.8%, respectively, in sickle cell anemia.…”

Section: Discussionmentioning

confidence: 99%

Serological prevalence of human parvovirus B19 in diseases or disordersrelated to different human body systems

2016

View full text Add to dashboard Cite

IntroductionHuman parvovirus B19 (B19), frequently seen all over the world, is a pathogenic agent associated with various diseases and disorders that affect different body systems. Erythema infectiosum, chronic arthritis, spontaneous abortion, hematological disorders, myocarditis, and glomerulonephritis are only some of these (1-3). B19 is spread from person to person by infected respiratory secretions, by infected blood and blood-product transfusions, and by vertical transmission from mother to fetus (4,5).B19-specific IgM antibodies appear 10-12 days after exposure to the virus and may be detected in serum for 3-6 months. IgG antibodies appear after approximately 2 weeks and persist for life (6). The prevalence of antibodies to B19 has been reported at higher rates in studies carried out in different geographic regions. Approximately 15% of preschool children, 50% of adults, and 85% of the elderly Background/aim: Human parvovirus B19 is a pathogen that affects different parts of the body. We planned this study because of the lack of data on B19 seroprevalence based on different body-system diseases. Materials and methods:The prevalence of parvovirus B19 antibodies was investigated retrospectively in 1239 patients by review of medical records from 2009-2012, according to their diseases classified under general titles in compliance with the International Classification of Diseases (ICD-10). Parvovirus B19-specific antibodies were detected by quantitative enzyme immunoassays. Results:The positivity rate was 27.8% for only IgG, 8.5% for only IgM, and 2.6% for both IgG and IgM. The highest positivity for IgG alone was found in musculoskeletal system and connective tissue diseases (55.9%), while the highest positivity for IgM was found in neoplasms (16.4%). The highest positivity for IgG was seen in rheumatoid arthritis (72.2%) and pregnancy (52.6%), and the highest positivity for total IgM was found in upper respiratory tract disease (21.0%) and hepatic failure (17.1%).Conclusions: Parvovirus B19 seroprevalence was relatively low in northeastern Anatolia compared to most serological studies conducted in other regions. We think that this study has provided the first wide-ranging information on the seroprevalence of B19 in diseases and disorders of the major human body systems.

show abstract

“…Acute erythroblastopenia is the first disease to be associated with parvovirus B19 [28]. In predisposed patients such as those affected with chronic hemolytic anemia, 70% to 80% of erythroblastopenia cases are caused by infection with this virus.…”

Section: Discussionmentioning

confidence: 99%

“…In predisposed patients such as those affected with chronic hemolytic anemia, 70% to 80% of erythroblastopenia cases are caused by infection with this virus. The infected patients usually become highly viremic and pose an increased risk of B19 virus transmission [28]. Close monitoring of such high-risk groups is required to acquire data on parvovirus infection for the formulation of epidemiological surveillance programs and prevention strategies.…”

Section: Discussionmentioning

confidence: 99%

Molecular and serological assessment of parvovirus B19 infections among sickle cell anemia patients

Obeid

2011

J Infect Dev Ctries

View full text Add to dashboard Cite

Introduction: Parvovirus B19 is a cause of hemolysis and red blood cell aplasia in patients with sickle cell anemia. The present study aimed to assess parvovirus B19 infection among sickle cell anemia patients. Methodology: All patients (n = 138) included in the study were sickle cell anemia patients. Blood donors were used as a control group. Assessment of parvovirus B19 antibodies and viral DNA was performed using established methods of detection and B19 recomBlot assay. Results: Detectable levels of parvovirus B19 IgG were found in 52 samples (37.6%) whereas anti-parvovirus B19 IgM antibodies were detected in four (2.89 %) patients of the sickle-cell anemia group. Anti-B19 IgM-positive samples contained B19-viral DNA. These four patients presented with fever, malaise, pallor and no cutaneous rash. Anti-parvovirus B19 antibodies were detected in 22 (39.3%) of the control blood donors group. Anti-parvovirus B19 IgM antibodies were not detected in the control group. Using the recomBlot assay, 58 test samples (42%) were found to contain detectable levels of Parvovirus B19 antibodies. All the samples that were positive for parvovirus B19 IgG by the ELISA were also positive by the recomBlot assay. Six samples were only positive by the recomBlot assay and not by the ELISA. Two of these six samples were positive for B19 viral DNA. Conclusions: Establishing the extent of parvovirus B19 infection in sickle cell anemia patients will help in proper management of aplastic crisis in such patients. The B19 recomBlot assay may be suitable as a confirmatory assay.

show abstract

Parvovirus B19 infection in Tunisian patients with sickle-cell anemia and acute erythroblastopenia

Cited by 25 publications

References 28 publications

Detection of human parvovirus B19 in cancer patients using ELISA and real-time PCR

Detection of human parvovirus B19 in cancer patients using ELISA and real-time PCR

Serological prevalence of human parvovirus B19 in diseases or disordersrelated to different human body systems

Molecular and serological assessment of parvovirus B19 infections among sickle cell anemia patients

Contact Info

Product

Resources

About